Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 5, 2025

The role of gip in carbohydrate metabolism: Implications in the development of therapies for T2DM, a narrative review.

View Full Paper
Ask AI
Bookmark
Share

Authors

DGDavid Almorza GomarADAlfredo Díaz-GómezFVFrancisco Visiedo

Discussion

Loading...

Member takes

Overview

Narrative review highlights GIP's role and analogues in carbohydrate metabolism, suggesting new therapies for T2DM.

Key Points

  • GIP has emerged as a significant target for developing therapies for T2DM due to its effects on insulin and glucagon.
  • Combined GIP/GLP-1 analogues like tirzepatide show potential for enhanced therapeutic efficacy in T2DM management.
  • The review discusses GIP physiology and its implications in carbohydrate metabolism and T2DM treatment strategies.
  • Understanding GIP and its dual/receptor activities offers promising avenues for future drug development against T2DM.

Cite This Study

Gomar et al. (2025) studied this question.

synapsesocial.com/papers/689a0f93e6551bb0af8d1292https://doi.org/10.14670/hh-18-967
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management2025 · 9 citations
  2. 2Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare2025 · 7 citations
  3. 3Novel GLP-1-Based Medications for Type 2 Diabetes and Obesity2025
  4. 4Editorial: Incretin-based therapies in the treatment of metabolic syndrome: expanding roles beyond weight management2025 · 1 citations
  5. 5Engineered nutrient-stimulated hormonal multi-agonist for precision targeting of obesity and metabolic disorders2025